LIFECARE

PRESS RELEASE
10 June 2026 07:00:00 CEST

LIFECARE COMPLETES FIRST SIX-MONTH IMPLANT EVALUATION WITH CONTINUED FUNCTIONALITY AND NO ADVERSE BIOLOGICAL RESPONSE

Bergen, Norway, 10 June 2026 - Lifecare ASA (LIFE) today announces successful completion of the company's first six-month implant evaluation in the veterinary study, LFC-SEN-002, representing the longest completed in-vivo assessment of a fully integrated Lifecare implant to date.

The implant that was implanted 9 December 2025, and removed 9 June 2026 in accordance with study protocol, following six months of continuous implantation under real-life conditions. The implant remained operational throughout the implantation period and continued to communicate with external equipment immediately following explantation.

Initial post-explantation observations demonstrated continued electronic functionality, no visible mechanical damage to the implant upon microscopic inspection, and an apparently intact sensor membrane following retrieval.

Importantly, no clinically significant adverse events, foreign body reactions, or other observable clinical effects beyond the intended monitoring function were observed during the six-month implantation period.

“This represents one of the most important development milestones achieved by Lifecare to date,” said Joacim Holter, Chief Executive Officer of Lifecare ASA.

“Long-term functionality and biocompatibility are fundamental requirements for implantable continuous glucose monitoring. Successfully completing six months of implantation without observing adverse biological response, while maintaining system functionality through explantation, provides important validation of both our implant platform and manufacturing approach.”

Real-life use supports individualized diabetes management

Throughout the six-month study period, continuous data was uploaded from the study system. Together with glucose measurements from reference monitoring devices and in-clinic blood glucose assessments, this provided the veterinary team at Norwegian School of Life Sciences (NMBU) with comprehensive data set for long-term diabetes management. The information supported ongoing clinical assessment and individualized treatment adjustments throughout the study period.

Unlike conventional veterinary glucose monitoring approaches, which typically provide only periodic measurements, the continuous availability of glucose information allowed closer follow-up of glucose trends and treatment response over time.

According to both the treating veterinarian and the dog's owners, the increased access to longitudinal monitoring data contributed to improved diabetes management and a noticeable improvement in the dog's quality of life during the study period.

The study has therefore provided not only important information regarding implant performance, durability and biocompatibility, but also practical experience demonstrating the potential value of continuous glucose monitoring in veterinary diabetes care.

Validation of reproducible manufacturing

The implant originated from the first reproducibly manufactured implant batch established following Lifecare's transition from prototype development toward reproducible manufacturing processes. Two additional implants manufactured from the same production batch remain active in the ongoing study and are progressing toward similar implantation durations.

"We are beginning to establish evidence not only of longevity and functionality, but of repeatable performance from reproducibly manufactured implants. This is a critical step in the transition from technology development toward scalable manufacturing, regulatory execution and commercialization," Holter continued.

Further analysis underway

The explanted implant will now be transferred for comprehensive laboratory evaluation, including assessment of sensor performance, chemistry status, implant condition and tissue response following six months in vivo.

The ongoing longevity program is designed to evaluate long-term implant performance, durability, biocompatibility and operational stability under real-life conditions. Results generated through the program continue to provide important input supporting product development, manufacturing scale-up, regulatory activities and future commercialization efforts.

Lifecare is currently preparing its next implant production campaign, planned to commence during July 2026, as part of the company's ongoing transition toward routine manufacturing operations in Bergen, Norway.

Further updates regarding laboratory analysis and long-term performance assessments will be communicated when available.

About LFC-SEN-002

LFC-SEN-002 is an ongoing longevity and performance study evaluating Lifecare's implantable CGM technology in dogs. The study focuses on biocompatibility, system stability, and in-vivo signal behaviour, and supports both veterinary product development and future human clinical programs. The study is conducted under veterinary supervision in cooperation with the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences. Data generated in the study provide direct input to Lifecare's ongoing development and execution program.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64